In brief
- A pilot trial at two hospitals in Ottawa, Canada, has tested daily oral psilocybin microdosing in people with advanced, incurable illnesses and severe psychological distress.
- Of the thirteen patients who completed the three-week treatment, 69% noted a relevant global improvement, and 72% reduced their level of demoralization.
- This is an open-label study without a control group and with a small sample size; the authors are already preparing a randomized trial to confirm the results.
A team from the University of Ottawa has published the results of PSYCHED-PAL, the first trial to evaluate daily psilocybin microdosing to alleviate the psychological and existential distress of people with advanced and incurable illnesses. The study, which appeared in the journal Palliative Medicine, points to clinically relevant improvements in depression, anxiety, and demoralization after only three weeks of treatment.
A microdosing protocol, not supervised sessions
Psychological and existential distress—the unease that arises when facing a terminal illness, characterized by fear, loss of meaning, or hopelessness—is common in palliative care and has, until now, lacked rapid and effective treatments. The team led by James Downar recruited twenty people between the ages of 40 and 84 at two Ottawa centers between January 2024 and April 2025; 82% had cancer and an estimated prognosis of one to twelve months. Instead of resorting to a high dose with intensive psychotherapeutic support, the standard model in psilocybin research, the design opted for a protocol of escalating microdoses taken daily at home: 1 mg per day during the first week, 2 mg in the second, and 3 mg in the third, without supervised dosing sessions.
What they found
Of the seventeen participants who began the regimen, thirteen (76%) completed the three weeks. Among those who finished, 69% showed a relevant global improvement; 62% reduced their depression score on the Hamilton scale by at least half; 54% achieved a similar improvement on the Hospital Anxiety and Depression Scale (HADS); and 72% showed a clinically significant reduction in demoralization, with large effect sizes according to the researchers themselves. No serious adverse events were recorded: there were nine mild or moderate episodes and four dropouts due to disease progression or insufficient response.
What it implies
These figures should be read with the caution that the design demands: it is a pilot, open-label study without a placebo group, with a small sample and a considerable dropout rate. Without a comparison group, the effect of expectations or support cannot be ruled out, which is particularly relevant in a context as sensitive as the end of life. The authors themselves acknowledge this and are already working on a randomized, controlled trial. Even so, the work provides a first indication that a microdosing protocol, which is much simpler to administer than high-dose sessions, could have a place in alleviating existential suffering. Evidence on microdosing is, for now, uneven: in other indications, results have been less favorable, as we reported when covering a review on LSD microdosing and ADHD. Those who wish to delve deeper into the state of research can consult our guide on psychedelic science and therapy.
Source
- Downar J, Lapenskie J, Anderson K, Parsons G, Polskaia N, Lalumiere G, Lawlor P. PSilocybin for psYCHological and existential distress in PALliative care (PSYCHED-PAL): A single arm unblinded clinical trial. Palliative Medicine, 2026;40(4):514-523, published online January 30, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
